top of page

Roche’s cancer immunotherapy drug has longer OS vs. chemotherapy

Roche’s study for tecentriq (atezolizumab) met its co-primary endpoints and showed a statistically significant and clinically meaningful improvement in overall survival (OS) compared with docetaxel chemotherapy in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed on or after treatment with platinum-based chemotherapy.


Click on this link for more information.

source: http://www.europeanpharmaceuticalreview.com/43671/news/industry-news/roche-cancer-study-chemotherapy/

#Pharmanews

Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page